

# Sehhoon Park

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2139686/publications.pdf>

Version: 2024-02-01

54  
papers

902  
citations

516710

16  
h-index

526287

27  
g-index

54  
all docs

54  
docs citations

54  
times ranked

1326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Artificial Intelligenceâ€‘Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Nonâ€‘Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	1.6	94
2	High liver fibrosis index FIBâ€‘4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. <i>Hepatology</i> , 2015, 61, 1261-1268.	7.3	90
3	Characteristics and Outcome of ROS1-Positive Nonâ€‘Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382.	1.1	77
4	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1640-1650.	1.1	64
5	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1758-1766.	1.1	60
6	Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. <i>PLoS ONE</i> , 2018, 13, e0189766.	2.5	46
7	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 134, 7-15.	2.0	38
8	High concordance of actionable genomic alterations identified between circulating tumor DNAâ€‘based and tissueâ€‘based nextâ€‘generation sequencing testing in advanced nonâ€‘small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028.	4.1	37
9	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. , 2019, 7, 128.		27
10	Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor. <i>Lung Cancer</i> , 2019, 127, 66-68.	2.0	26
11	Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1140-1149.	1.7	26
12	Longitudinal monitoring by nextâ€‘generation sequencing of plasma cellâ€‘free <sc>DNA</sc> in <sc>ALK</sc> rearranged <sc>NSCLC</sc> patients treated with <sc>ALK</sc> tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2022, 11, 2944-2956.	2.8	24
13	Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 900-908.	1.1	23
14	Biomarkerâ€‘driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinumâ€‘based chemotherapy. <i>Cancer</i> , 2020, 126, 4002-4012.	4.1	22
15	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 514-522.	1.7	21
16	Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <i>Cancer</i> , 2022, 128, 2148-2158.	4.1	19
17	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016, 16, 425-433.	1.7	18
18	Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the <sc>FIB</sc>â€‘4 liver fibrosis index. <i>Cancer</i> , 2015, 121, 3818-3825.	4.1	17

#	ARTICLE	IF	CITATIONS
19	Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. <i>Apmis</i> , 2017, 125, 699-707.	2.0	12
20	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. <i>Lung Cancer</i> , 2018, 124, 293-297.	2.0	12
21	<i>EGFR</i> C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with <i>EGFR</i> T790M Mutation. <i>Cancer Research and Treatment</i> , 2020, 52, 1288-1290.	3.0	12
22	Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal: added value of contrast-enhanced 2D axial T2 FLAIR. <i>Journal of Neuro-Oncology</i> , 2020, 149, 367-372.	2.9	10
23	Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8514-8514.	1.6	10
24	Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 42-53.	2.8	10
25	Mild form of Guillain-Barré syndrome in a patient with primary Epstein-Barr virus infection. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 1191-1193.	1.7	9
26	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 415-425.	0.8	9
27	Evaluating entrectinib as a treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1935-1942.	1.8	8
28	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1315-1325.	3.4	8
29	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
30	Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4312-4321.	7.0	7
31	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?. <i>Biology</i> , 2020, 9, 326.	2.8	6
32	Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. <i>European Journal of Cancer</i> , 2021, 159, 167-173.	2.8	6
33	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4209-4220.	2.8	6
34	Early repolarization is associated with significant coronary artery stenosis in asymptomatic adults. <i>Atherosclerosis</i> , 2016, 245, 50-53.	0.8	5
35	The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8562-8562.	1.6	5
36	Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9603-9603.	1.6	5

#	ARTICLE	IF	CITATIONS
37	Lung Cancer in Korea. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1988-1993.	1.1	5
38	Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. <i>BMB Reports</i> , 2021, 54, 386-391.	2.4	4
39	Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. <i>Translational Lung Cancer Research</i> , 2021, 10, 3865-3874.	2.8	4
40	A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
41	A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG Tj ETQq1 1 0.784314 rgBT <sub>2</sub> /Overlook	1.6	0
42	A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9636-TPS9636.	1.6	2
43	Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-“Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. <i>Cancer Research and Treatment</i> , 2023, 55, 344-349.	3.0	2
44	In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing. <i>Journal of Thoracic Oncology</i> , 2019, 14, e279-e280.	1.1	1
45	Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9094-9094.	1.6	1
46	The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2621-2621.	1.6	1
47	Long-term Survival in Non-“Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. <i>Cancer Research and Treatment</i> , 2022, 54, 150-156.	3.0	0
48	Distinct subset of immune cells assessed by multiplex immunohistochemistry correlates with immune phenotype classified by an artificial intelligence-powered tissue analyzer in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21012-e21012.	1.6	0
49	Abstract 1908: Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes reveals distinct genomic profile of immune excluded phenotype in pan-carcinoma. , 2021, , .		0
50	Deep-learning analysis of CT imaging biomarker for PD-L1 expression to predict heterogeneous response to immune checkpoint inhibitors in non-small cell lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21529-e21529.	1.6	0
51	The 10-year journey of non-“small cell lung cancer: A real-world experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9133-9133.	1.6	0
52	Solid tumor patients with G12V and G13D <i>KRAS</i> aberrations have poor survival following ICI treatment.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14567-e14567.	1.6	0
53	Landscape of tumor mutation burden and correlation to clinical outcomes in 1,744 solid cancers.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2667-2667.	1.6	0
54	Exploratory analysis using cfDNA-based fragmentomics to predict disease recurrence in limited disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8569-8569.	1.6	0